N/A
N=59
Standardized Patients to Measure and Address Intersectional Stigma
Hiv · HIV Infections · AIDS
Bottom Line
View on ClinicalTrials.gov: NCT04896216 ↗Enrolled (actual)
59
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: MSM Stigma; Domain of Care: Syphilis Testing — 0.078; 0.034 percentage points
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Stigma Reduction Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MSM Stigma; Domain of Care: Syphilis Testing |
0.078; 0.034 | — |
| PRIMARY HIV Stigma; Domain of Care: Syphilis Testing |
-0.201; 0.034 | — |
| PRIMARY Intersectional Stigma; Domain of Care: Syphilis Testing |
-0.07; 0 | — |
| PRIMARY MSM Stigma; Domain of Care: Diagnostic Effort |
-0.055; 0.396 | — |
| PRIMARY HIV Stigma; Domain of Care: Diagnostic Effort |
-0.570; 0.396 | — |
| PRIMARY Intersectional Stigma; Domain of Care: Diagnostic Effort |
0.621; 0.396 | — |
| PRIMARY MSM Stigma; Domain of Care: Patient-centered Care |
-0.168; -0.162 | — |
| PRIMARY HIV Stigma; Domain of Care: Patient-centered Care |
0.408; -0.162 | — |
| PRIMARY Intersectional Stigma; Domain of Care: Patient-centered Care |
-0.165; -0.162 | — |
Summary
This study aims to develop and evaluate an intervention to reduce enacted stigma in healthcare settings aimed at people living with HIV (PLWH) and men who have sex with men (MSM) in China. Enacted stigma will be measured using a quality of care score collected through unannounced standardized patient (SP) visits to consenting providers in sexual health clinics.
Eligibility Criteria
Inclusion Criteria
- Eligible facilities will be those with:
- formal government accreditation as a medical center (a basic tenet of all public hospitals in China); and
- possession of an accredited on-site laboratory with capacity to provide enzyme-linked immunosorbent assay testing for HIV, treponemal (e.g. Treponema pallidum particle agglutination) and non-treponemal tests (e.g. rapid plasma regain) for syphilis.
- Within eligible and consenting facilities, eligible providers will be those who are licensed at the time of the study to practice dermatovenereology in China.
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT04896216). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.